BC Week In Review | Oct 29, 2007
Clinical News

AERx nicotine: Phase I data

In an open-label Phase I trial in 18 adult smokers, single 0.2, 0.4 and 0.7 mg doses of AERx nicotine were well tolerated. In the low-, medium- and high-dose groups, mean craving scores were reduced...
Items per page:
1 - 1 of 1